推薦產品
product name
Methotrexate,
化驗
≥98% (HPLC)
品質等級
形狀
solid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
yellow
溶解度
DMSO: 100 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
InChI
1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
InChI 密鑰
FBOZXECLQNJBKD-ZDUSSCGKSA-N
一般說明
Inhibits thymidylate synthetase, is a nonselective de novo purine synthesis inhibitor and has a significant toxicity profile including hepatotoxicity, pneumonitis and bone marrow suppression. Potent folic acid antagonist. Induces apoptosis in HL-60 human leukemia cells. Also useful as an anti-tumor agent.
警告
Toxicity: Toxic (F)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
其他說明
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Kaufman, S.H., et al. 1993. Cancer Res.53, 3976.
Takasuga, A., et al. 1992. J. Biochem.112, 652.
Hirata, S., et al. 1989. Arthritis Rheum. 32, 1065.
Jolivet, J., et al. 1983. New Engl. J. Med. 309, 1094.
Takasuga, A., et al. 1992. J. Biochem.112, 652.
Hirata, S., et al. 1989. Arthritis Rheum. 32, 1065.
Jolivet, J., et al. 1983. New Engl. J. Med. 309, 1094.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
訊號詞
Danger
危險分類
Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1
標靶器官
Liver,Bone marrow
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Ofer Shoshani et al.
Nature, 591(7848), 137-141 (2020-12-29)
Focal chromosomal amplification contributes to the initiation of cancer by mediating overexpression of oncogenes1-3, and to the development of cancer therapy resistance by increasing the expression of genes whose action diminishes the efficacy of anti-cancer drugs. Here we used whole-genome sequencing
Lukas Westermann et al.
Scientific reports, 12(1), 18211-18211 (2022-10-29)
Genome editing tools such as CRISPR/Cas9 enable the rapid and precise manipulation of genomes. CRISPR-based genome editing has greatly simplified the study of gene function in cell lines, but its widespread use has also highlighted challenges of reproducibility. Phenotypic variability
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務